Teva recently released the following press release looking at the effectiveness and patient satisfaction for HD chorea with the 4 week titration kit for AUSTEDO®.
Quick Notes
- Titration of a medicine means slowly increasing the dose of a medicine by very small amounts over days, weeks, or even months, to find the right dose that is effective for you
- Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results
- START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4-week Titration Kit for AUSTEDO
- AUSTEDO remains the only vesicular monoamine transporter 2 (VMAT2) inhibitor available with 3-year data for this progressive condition1,2